Fintel reports that on January 8, 2026, BTIG initiated coverage of Bicara Therapeutics (NasdaqGM:BCAX) with a Buy recommendation.
Analyst Price Forecast Suggests 100.38% Upside
As of December 21, 2025, the average one-year price target for Bicara Therapeutics is $33.22/share. The forecasts range from a low of $11.11 to a high of $50.40. The average price target represents an increase of 100.38% from its latest reported closing price of $16.58 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual non-GAAP EPS is -2.44.
What is the Fund Sentiment?
There are 225 funds or institutions reporting positions in Bicara Therapeutics. This is an decrease of 1 owner(s) or 0.44% in the last quarter. Average portfolio weight of all funds dedicated to BCAX is 0.49%, an increase of 31.79%. Total shares owned by institutions decreased in the last three months by 1.96% to 52,374K shares. 
The put/call ratio of BCAX is 10.44, indicating a bearish outlook.
What are Other Shareholders Doing?
Ra Capital Management holds 6,956K shares representing 12.70% ownership of the company. No change in the last quarter.
Siren, L.L.C. holds 5,217K shares representing 9.52% ownership of the company. No change in the last quarter.
Vestal Point Capital holds 5,100K shares representing 9.31% ownership of the company. In its prior filing, the firm reported owning 5,000K shares , representing an increase of 1.96%. The firm increased its portfolio allocation in BCAX by 48.70% over the last quarter.
Red Tree Management holds 3,171K shares representing 5.79% ownership of the company. No change in the last quarter.
Tpg Gp A holds 3,010K shares representing 5.50% ownership of the company. No change in the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
